|| List of recent Antibodies-related patents
|Antibodies to ccr2|
Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ccr2, preferably human ccr2, and that may inhibit ccr2. The present antibodies may bind to the first and/or second extracellular loops of ccr2.
|Neutralizing gp41 antibodies and their use|
Monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids.
|Dna encoding function modifying nav1.7 antibodies|
A nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.. .
|Vascular endothelial growth factor 2|
Disclosed are human vegf-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies.
|Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis|
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue.
|Method for the detection of an analyte in a sample|
A method for the detection of at least one analyte in a sample is disclosed, wherein it comprises the steps of: a) providing a layer comprising a porous matrix having at least one ligand bound thereto above a filter constituting the bottom of at least one well of an assay plate, wherein said filter does not allow passage of said porous matrix having a ligand bound thereto, b) adding a sample containing said at least one analyte to be detected, said at least one analyte having the ability to specifically bind to said at least one ligand, c) adding a wash solution with a view to washing out non-bound sample components from the assay plate through the filter, d) adding enzyme-linked antibodies or antigens having the ability to specifically bind to said at least one analyte, e) adding a wash solution with a view to washing out non-bound enzyme-linked antibodies or antigens from the analysis plate through the filter, f) adding a substrate specific for the enzyme, wherein a product is formed by a reaction between the enzyme and the substrate, determining the quantity of said at least one analyte by measuring a signal related to the product, as well as method for the diagnosis of an ehec (enterohemorrhagic escherichia coli) infection or hus (hemolytic uremic syndrome), wherein a body sample from a patient is added as the sample and the analyte is detected using the above disclosed method, wherein the saccharide in the ligand is galα1-gal or galα1-4galβ1-4glc.. .
|Nanoengineering of functionalized polymers and its manufacturing and formulation methods for personalized cancer therapies|
Nanoengineering of inert polymers to develop functionalized sulfonated polymers to harness the power of alternate complement system to stimulate and amplify cytotoxic potentials of classical and lectin based complement system manufacturing functionalized sulfonated polymer to better penetrate tumor microenvironment, actively target various cancer antigens in conjunction with monoclonal antibodies in a safe way to inhibit host inflammatory reactions while maximizing cytotoxic potentials. The methods provide nanopolymers to safely maximize the cytotoxic potential of existing and evolving cancer therapies.
|Ehrlichia ewingii proteins, nucleic acids, and methods of their use|
The novel omp-1 gene cluster encoding twenty one ehrlichia ewingii (ee) proteins was isolated and sequenced completely. This invention relates to isolated e.
|Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof|
Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza b viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza a viruses.
|Stabilized formulations containing anti-pcsk9 antibodies|
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (pcsk9). The formulations may contain, in addition to an anti-pcsk9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant.
|Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities|
The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (sod1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the international depositary authority of canada on aug.
|Formulation of human antibodies for treating tnf-alpha associated disorders|
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a ph of between about 4 and about 8, and enhanced stability.. .
|Formulation of human antibodies for treating tnf-alpha associated disorders|
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a ph of between about 4 and about 8, and enhanced stability.. .
|Human rhinovirus (hrv) antibodies|
The invention provides isolated fully human monoclonal anti-hrv antibodies, as well as method of making and using these antibodies. Anti-hrv antibodies of the invention prevent or treat subjects having hrv-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (copd), sinusitis, bacterial superinfection, and cystic fibrosis..
|Anti-pd-l1 antibodies and uses thereof|
The present application relates to anti-pd-l1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.. .
|Therapeutic combinations and methods of treating melanoma|
The invention provides therapeutic combinations of anti-etbr antibodies and map kinase inhibitors and methods of using the same to treat melanoma.. .
|Methods and compositions for treating asthma using anti-il-13 antibodies|
The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-il-13 antibody, or antigen-binding portion thereof.. .
|Monoclonal antibodies directed to cd52|
The invention provides antibody to canine or feline or equine antigens, e.g., canine cd52, and methods of making and using antibodies as described.. .
|Anti-human cd52 immunoglobulins|
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human cd52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain.
|Compositions and methods of use for antibodies of dickkopf-1|
Antibodies and fragments that bind to the protein target dickkopf (dkk1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.. .
|Silent fc variants of anti-cd40 antibodies|
The present invention relates to silent fc variants of anti-cd40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.. .
|Anti-folate receptor alpha antibodies and uses thereof|
Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits.
|Humanized anti-human nkg2a monoclonal antibody|
The present invention relates to agents that are non-competitive antagonists of the cd94/nkg2a receptor such as certain anti-nkg2a antibodies, in particular humanized versions of murine anti-nkg2a antibody z199, as well as methods of producing and using such agents and antibodies.. .
|Anti-alpha2 integrin antibodies and their uses|
The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the i domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen.
|Treatment with anti erbb2 antibodies|
The present invention concerns the treatment of disorders characterized by the overexpression of erbb2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing erbb2 with a combination of an anti-erbb2 antibody and a chemotherapeutic agent other than an anthracycline, e.g.
|Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer|
This invention relates to the treatment of cancer using anti-erbb antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (il2) conjugates which target tenascin-c.. .
|Antagonists for abdominal vasopressin v2 receptor and uses thereof|
Provided herein are antagonists or binding agents of an abnormal vasopressin receptor v2 (e.g., abnv2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor v2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro.
|Provasopressin antagonists and uses thereof|
Provided herein are pro-vp antagonists, such as antibodies and antigen-binding portions thereof specific for pro-vp, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples.
|Cdr regions of monoclonal antibody that antagonize sphinogosine 1-phosphate and related methods|
Materials and method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3.
|Antibodies against human csf-1r and uses thereof|
The present invention relates to antibodies against human csf-1r (csf-1r antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
|Avian derived antibodies|
The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-cd20 antibody molecules produces in a transgenic avian. The antibody molecules have a heavy chain and a light chain and exhibit an increased level of antibody-dependent cell-mediated cytotoxicity (adcc) as compared to that of anti-cd20 antibody molecules produced by cho cells..
|Assembly of bispecific antibodies|
Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule.
|Tyrosine, serine and threonine phosphorylation sites|
The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including aqua peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.. .
|Virus vectors for highly efficient transgene delivery|
The invention provides viral vector formulations and methods of uses thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. The formulations include a vector and suitable amounts of empty capsids, viral genome-containing capsids, or viral capsid proteins which are optionally chemically or structurally modified and which bind to neutralizing anti-aav antibodies thereby reducing or preventing antibody-mediated clearance of the vector, but still allowing the genome-containing (therapeutic) vector to transduce target cells and achieve therapeutic gene transfer..
|Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof|
Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin d derivative, such as 25-hydroxyvitamin d2 and/or 25-hydroxyvitamin d3, or a 25-hydroxyvitamin d analog, such as a vitamin d-c22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described.
|Means and methods for recognizing the development of cardiovascular disease in an individual|
A method of recognizing the development of an acute myocardial infarction (ami) process in an individual, wherein the method comprises steps of: profiling specific antibody reactivities or biomarkers associated with ami susceptibility, the profiling comprises steps of: attaching a set of defined antigens to a substrate; obtaining a biological fluid derived specimen from an individual, the specimen containing a specific antibody repertoire; and binding said antibodies of the biological fluid specimen to the attached antigens thereby forming bound antibody antigen complexes; and analyzing results obtained, wherein the presence of the complexes is indicative of ami.. .
|Assay buffer, compositions containing the same, and methods of using the same|
The invention relates to improved electrochemiluminescence assay methods for phosphorylated peptides or proteins employing phospho-specific antibodies and buffer compositions that are substantially free of inorganic phosphate.. .
|Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit|
Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.. .
|Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms|
The present invention relates to polynucleotides from cochliobolus heterostrophus c5, cyanothece sp. Ccy0110, mycocentrospora acerin and hyaloperonospora parasitica, which code for desaturases and which can be employed for the recombinant production of polyunsaturated fatty acids.
|Stabilized human igg2 and igg3 antibodies|
It is intended to provide highly stable variants of human antibody igg2 and igg3 subclasses. The present invention provides an igg heavy chain comprising the constant region of a human igg2 heavy chain having at least a substitution of y for f at the 300th position, l for v at the 309th position, or a for t at the 339th position designated by the eu index of kabat et al.
|Method for producing phosphoserine incorporated proteins by using seprs mutants and ef-tu mutants|
According to the invention, a phosphorylated protein can be produced in an amount of mg per liter using the seprs and ef-tu mutants. Thus, the invention is useful for the production of various phosphorylated proteins, including phosphorylated enzymes, the production of antibodies, the fabrication of protein chips, and cell-based screening for new drug development..
|Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays|
The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy.
|Method of detecting the presence of an antibody in a sample|
Methods for detecting in a sample the presence of an antibody to a conjugate of an antigen associated with a first carrier by a first association are disclosed. The method comprises contacting a conjugate of the antigen associated with a second carrier by a second association with said sample under conditions that allow binding of the antibody to the antigen; and introducing an agent to detect the presence of the antibody bound to said antigen.
|Antibodies to clostridium difficile spores and uses thereof|
The present invention provides antibodies that bind to the endospore of the bacterium clostridium difficile, methods of making such antibodies, and methods of using such antibodies, including methods of detecting c. Difficile endospores..
|Method of diagnosing bacterial infections using bacterial glycoproteins|
The present application provides a method of diagnosing bacterial infections using engineered glycoproteins in an immunoassay. The engineered bacterial glycoproteins used in the immunoassay comprise a bacterial antigen covalently attached to a protein via polysaccharyltransferase (ptase)-mediated glycosylation, wherein the bacterial antigen is selected based on the bacterial infection of interest.
|Methods of diagnosing als|
The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent.
|Method for detecting an infection by the hepatitis c virus|
The invention relates to a method of in-vitro detection of an infection with a hepatitis c virus (hcv) in a biological sample, comprising the simultaneous detection of the hcv capsid protein, and of an antibody directed against said capsid protein, said method using, for capturing the anti-capsid antibodies, a peptide comprising an antigenic fragment derived from the truncated hcv capsid. The invention also relates to the peptide for capturing the anti-capsid antibodies and the kits comprising it..
|Anti-cd79b antibodies and immunoconjugates and methods of use|
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.. .
This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier.
|Therapeutic human anti-il-1r1 monoclonal antibody|
Antibodies that interact with interleukin-1 receptor type 1 (il-1r1) are described. Methods of treating il-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to il-1r1 are described.
|Method of isolating human antibodies|
Provided is a novel method of isolating and producing human antibodies with desired specificity from human b cells. In particular, a method of isolating human antibodies from memory b cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described..
|Anti-glucagon antibodies and uses thereof|
Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients in which glucagon signaling is implicated in pathogenesis..
|Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response|
The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria.
|Mammalian cytokines; related reagents and methods|
Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided..
|Pd-1 antibodies and pd-l1 antibodies and uses thereof|
The invention relates to pd-1 antibodies and pd-l1 antibodies and uses thereof.. .
|Compositions and methods for immunization against drug resistant acinetobacter baumannii|
The present invention provides vaccine compositions comprising ompa, or antigenic fragments thereof, and related methods of active immunization against a. Baumannii infection.
|Anti-glucagon receptor antibodies and methods of use thereof|
The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome..
|Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders|
Methods of treating or delaying onset of a neurodegenerative disorder with α-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble α-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with α-synuclein pathology is characterized by deposition of lewy bodies and lewy neurites or is selected from the group consisting of parkinson's disease (pd), dementia with lewy bodies (dlb), the lewy body variant of alzheimer's disease, and multiple system atrophy (msa)..
A new fusion protein which can specifically suppress the autoantibodies, which can effectively prevent or treat the autoimmune disease of autoantibody type, and which can be expressed in an amount sufficient for industrial production. A fusion protein, characterized in that, a protein (x) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type is connected to a protein (a) containing a fragment of the antibody heavy chain constant region which exhibits the antibody-dependent cellular cytotoxicity with a linker peptide (l) consisting of one or more amino acid(s), wherein the protein (x), the linker peptide (l) and the protein (a) are connected in this order by means of peptide bond from n terminal to c terminal..
|Humanized monoclonal antibodies to hepatocyte growth factor|
The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. .
|Influenza hemagglutinin antibodies, compositions and related methods|
Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.. .
The present invention relates inter alia to fertile non-human vertebrates such as mice and rats useful for producing antibodies bearing human variable regions, in which endogenous immunoglobulin chain expression has been inactivated.. .
|Antibodies, variable domains & chains tailored for human use|
The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells.
|Transgenic non-human assay vertebrates, assays and kits|
The invention provides assay vertebrates comprising a human antigen or epitope knock-in for testing antibodies comprising human variable regions and generated in a related antibody-generating vertebrate. The invention also provides kits and methods involving these vertebrates and antibodies.
|Carbon nanostructure electrochemical sensor and method|
Carbon nanostructures may be protected and functionalized using a layer-by-layer method whereby functional groups on the carbon nanostructure surface may be further derivatized to incorporate additional functional moieties. Exemplary moieties include redox mediator molecules, crown ethers, catalysts, boric acids, carbohydrates, oligonucleotides, dna or rna aptamers, peptide aptamers, proteins such as enzymes and antibodies, quantum dots and nanoparticles, cells, cell organelles, or other cellular components.
|Tissue specific expression of antibodies in chickens|
Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg.
|Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker|
Provided herein are methods for predicting efficacy of a dna (cytosine-5)-methyltransferase 1 (dnmt1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a dnmt1 inhibitor treatment, and methods of selecting a treatment for a subject having a cancer that include determining a level of sox9 in a sample containing cells from a subject having a cancer. Also provided are methods of treating a subject having a cancer that include selectively administering a dnmt1 inhibitor to a subject having cancer determined to have an elevated level of sox9 in a sample containing cells from the subject compared to a reference level.
|Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same|
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
|Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage|
The method and kit of the invention have the advantage to provide a specific, simple and early detection of kidney injury markers that is no possible with the standard methods applied until now. The method and kit of the invention also provide the advantage of identifying the specific structure that is injured in the kidney, since it uses specific antibodies for specific proteins present in specific structures of the kidney..
|Nanoantibodies, binding chlamydia trachomatis antigen, method for inhibition of infection induced by chlamydia trachomatis|
A nanoantibody specifically binding surface antigen of chlamydia trachomatis and having seq id no:2 amino acid sequence is disclosed. A nanoantibody specifically binding surface antigen of chlamydia trachomatis and having seq id no:4 amino acid sequence is disclosed.
|Method for producing human monoclonal immunoglobulin g antibodies|
The present invention a method for producing a human immunoglobulin g (igg) antibody using a prime-boost regime in a bone marrow liver thymic (blt) mouse.. .
|Activated t cells|
Provided are compositions comprising activated t cells and activated t cells armed with bispecific antibodies directed at cancer antigens which are poor responders to alloantigen, and methods of using the compositions to help engraftment and improve anti-tumor effects.. .
|Compositions for cell culture and methods of using the same|
Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function..